Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Raltitrexed: current clinical status and future directions

Tools
- Tools
+ Tools

Van Cutsem, E., Cunningham, D., Maroun, J., Cervantes, A., Glimelius, B. (2002) Raltitrexed: current clinical status and future directions. ANNALS OF ONCOLOGY, 13 (4). pp. 513-522. ISSN 0923-7534

Full text not available from this repository.

A copy of the full text may be available at: http://annonc.oxfordjournals.org/cgi/content/full/...

Abstract

Raltitrexed ('Tomudex') monotherapy is a conveniently administered alternative to 5-fluorouracil (5-FU) in the first-line treatment of advanced colorectal cancer (CRC), and has single-agent activity in a variety of advanced solid tumours. Although both raltitrexed and 5-FU are thymidylate synthase inhibitors, raltitrexed has a specific mode of action and a toxicity profile distinct from 5-FU. The mechanism of action of raltitrexed is also completely different from that of oxaliplatin. irinotecan and other drugs with which it has been combined. These properties. together with preclinical data. suggested that combinations of raltitrexed with 5-FU. other chemotherapeutic agents, or radiotherapy could result in improved therapies for a variety of advanced solid tumours, including advanced CRC. This review outlines the appropriate management of patients treated with raltitrexed. whether as monotherapy or in combination, and discusses the preliminary results of combination studies with raltitrexed in a range of turnout types including advanced CRC, malignant mesothelioma. gastric, pancreatic, head and neck, and non-small-cell lung cancers. Of particular interest is the combination of raltitrexed and oxaliplatin, which has shown promising antitumour effects in first-line treatment of advanced CRC and malignant mesothelioma, a disease that is refractory to chemotherapy.

Item Type: Review Article
Authors (ICR Faculty only): Cunningham, David
All Authors: Van Cutsem, E., Cunningham, D., Maroun, J., Cervantes, A., Glimelius, B.
Uncontrolled Keywords: colorectal cancer; 5-fluorouracil; mesothelioma; oxaliplatin; raltitrexed METASTATIC COLORECTAL-CANCER; FIRST-LINE TREATMENT; MULTICENTER RANDOMIZED TRIAL; PHASE-I; LEVOFOLINIC ACID; 5-FLUOROURACIL; LEUCOVORIN; FLUOROURACIL; OXALIPLATIN; TOMUDEX
Research teams: Clinical Units > Gastrointestinal Unit
Depositing User: Users 10 not found.
Date Deposited: 21 Jul 2008 10:01
Last Modified: 10 Feb 2010 11:49
URI: http://publications.icr.ac.uk/id/eprint/6653

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust